JAK2 and leukemia: Such work should not only lead to advances in cancer therapy, but also provide clues as to why some cells harboring mutations, such as JAK2, fail to drive aberrant clonal hematopoiesis, whereas others lead to MPNs, progressive disease, and lethal leukemia.